# Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

> **NCT01073644** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib malate

## Key facts

- **NCT ID:** NCT01073644
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no safety concerns that led to the decision to terminate.
- **Last updated:** 2013-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073644, "Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01073644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*